Cardinal Health, Inc. is rated a Buy with a $239 fair value, driven by specialty growth in autoimmune, urology & oncology.

Cardinal Health, Inc. (NYSE:CAH) will release earnings results for the fourth quarter before the opening bell on Tuesday, Aug ...

Analysts expect the health care company to report quarterly earnings at $2.03 per share, up from $1.84 per share in the ...

Healthcare distributor and services company Cardinal Health (NYSE:CAH) will be announcing earnings results this Tuesday ...

Key Insights Institutions' substantial holdings in Cardinal Health implies that they have significant influence ...

U.S. stock futures are down, with earnings from Cardinal Health Inc. and Sea Ltd. to watch. ZipRecruiter Inc. beats ...

Cardinal Health, Inc. CAH is scheduled to report fourth-quarter fiscal 2025 results on Aug. 12, before market open. In the ...

Wall Street analysts forecast that Cardinal Health (CAH) will report quarterly earnings of $2.03 per share in its upcoming release, pointing to a year-over-year increase of 10.3%. It is anticipated ...

Approximately six in 10 U.S. adults reported taking a prescription drug, and a quarter of U.S. adults take four or more.

Headquartered in Columbus, Ohio, Cardinal Health is a global, integrated healthcare services and products company that generated $205 billion in revenue in its fiscal year 2023. The company plays ...

Cardinal Health’s revenue rising 33% to $181 billion over the last twelve months, compared to $137 billion in 2017, 2. a 6% fall in its total shares outstanding to 294 million, partly offset by ...

Cardinal Health Inc. is exploring a potential sale of its nuclear medicine business as part of a larger review of its strategy and operations, according to people familiar with the matter.